These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

634 related items for PubMed ID: 28228105

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM.
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [Abstract] [Full Text] [Related]

  • 23. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma.
    Kipriyanov SM, Cochlovius B, Schäfer HJ, Moldenhauer G, Bähre A, Le Gall F, Knackmuss S, Little M.
    J Immunol; 2002 Jul 01; 169(1):137-44. PubMed ID: 12077238
    [Abstract] [Full Text] [Related]

  • 24. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
    Xiong D, Xu Y, Liu H, Peng H, Shao X, Lai Z, Fan D, Yang M, Han J, Xie Y, Yang C, Zhu Z.
    Cancer Lett; 2002 Mar 08; 177(1):29-39. PubMed ID: 11809528
    [Abstract] [Full Text] [Related]

  • 25. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
    Haagen IA.
    Leuk Lymphoma; 1995 Nov 08; 19(5-6):381-93. PubMed ID: 8590837
    [Abstract] [Full Text] [Related]

  • 26. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
    Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA.
    Blood; 2015 Jun 18; 125(25):3905-16. PubMed ID: 25940712
    [Abstract] [Full Text] [Related]

  • 27. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
    Haagen IA, van de Griend R, Clark M, Geerars A, Bast B, de Gast B.
    Clin Exp Immunol; 1992 Dec 18; 90(3):368-75. PubMed ID: 1281055
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
    Wu J, Fu J, Zhang M, Liu D.
    J Hematol Oncol; 2015 Sep 04; 8():104. PubMed ID: 26337639
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Construction of tandem diabody (IL-6/CD20)-secreting human umbilical cord mesenchymal stem cells and its experimental treatment on diffuse large B cell lymphoma.
    Zhang J, Zhong M, Zhong W, Lan Y, Yuan Z, Duan Y, Wei Y.
    Stem Cell Res Ther; 2022 Sep 14; 13(1):473. PubMed ID: 36104733
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
    Klein SC, Boer LH, de Weger RA, de Gast GC, Bast EJ.
    Scand J Immunol; 1997 Nov 14; 46(5):452-8. PubMed ID: 9393627
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.
    Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD, Andrews C, Matsuzaki J, Valmori D, Ayyoub M, Frederick PJ, Beck A, Liao J, Cheney R, Moysich K, Lele S, Shrikant P, Old LJ, Odunsi K.
    Cancer Res; 2009 Jul 01; 69(13):5498-504. PubMed ID: 19491279
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells.
    d'Argouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, Suzich J, Locher M, Kiener P, Kufer P, Hofmeister R, Baeuerle PA, Bargou RC.
    Leuk Res; 2009 Mar 01; 33(3):465-73. PubMed ID: 18835037
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.